has confirmed that epidermal growth factor receptor mutation (EGFRvIII)‐activated mTORC2 signalling promotes GBM proliferation and chemotherapy resistance through the Akt‐independent activation of the NF‐κB pathway.22 Here, NFKB1 is linked to glioblastoma.